TBC1D3G Antibodies

Santa Cruz Biotechnology offers a broad range of TBC1D3G monoclonal antibodies for investigating TBC1D3G's role in cellular processes. The monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). TBC1D3G belongs to the TBC (Tre-2/Bub2/CDC16) domain family and plays a significant role in regulating cellular signaling pathways and vesicle trafficking. TBC1D3G actively participates in insulin signaling and glucose homeostasis, making it a crucial component in metabolic regulation. Research focusing on TBC1D3G has revealed its potential involvement in various metabolic disorders, including obesity and diabetes. Scientists studying TBC1D3G can uncover new therapeutic targets and treatment strategies for metabolic diseases. Understanding TBC1D3G's molecular mechanisms can lead to breakthroughs in cellular biology and disease treatment. Investigating TBC1D3G's functions helps reveal its impact on human health and disease development. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of TBC1D3G's role in human health and disease.